Recursion Pharmaceuticals, Inc. (RXRX) bonds
RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.72−0.18 (-6.37%)
Close on Nov 17, 2026Market cap $1.46BP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$14.20M
$9.44M due within a year
Net debt
-$531.49M
After $545.68M of cash
Implied interest rate
7.85%
FY2025 interest ÷ average debt
Interest coverage
-358.1×
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2021
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Recursion Pharmaceuticals's 10-Q for the period ended Mar 31, 2024
| Issue | Coupon | Carrying value |
|---|---|---|
| Station 41 lease | 8.00% | $510.00K |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?